Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Sarcoma 2Head & Neck 2Breast 2Plasma cell 1Other hematologic neoplasm 1NET 1Myeloid 1Lymphoid 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 4Differentiated Thyroid Cancer 2Adenoma, Islet Cell 2Tuberous Sclerosis 1Thyroid Cancer, Papillary 1Pituitary Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Insulinoma 1Hyperinsulinism 1Growth Hormone-Secreting Pituitary Adenoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Congenital Hyperinsulinism 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Advanced Extrapulmonary Neuroendocrine Cancer 1Adenocarcinoma, Follicular 1Acromegaly 1

Interventions

Everolimus 5pembrolizumab 2cabozantinib 2Trastuzumab 2Nivolumab 2vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1spartalizumab 1romidepsin 1regorafenib 1pentetreotide 1guadecitabine 1fostamatinib 1exemestane 1entrectinib 1entinostat 1belzutifan 1avelumab 1alectinib 1Vinorelbine 1Sirolimus 1Rosiglitazone 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Nephrectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Injections × Endocrine × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡